Tannapfel A, Nüsslein S, Fietkau R, Katalinic A, Köckerling F, Wittekind C
Institute of Pathology, University of Leipzig, Germany.
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585-91. doi: 10.1016/s0360-3016(98)00076-5.
To investigate the relationship between apoptotic cell death, proliferative activity, and the expression of apoptosis regulating proteins in rectal cancer prior to and after radiochemotherapy.
In 32 patients dispositioned to receive preoperative radiochemotherapy for locally advanced rectal carcinoma, pretherapy biopsies and the final resected specimen after radiochemotherapy were available for analyses. Apoptotic cells were identified and quantified using in situ end labeling (ISEL) technique. The expression of the bax protein was assessed immunohistochemically. Additionally, double immunostaining was performed for apoptotic cells and bax expression. The proliferative activity was determined by immunohistochemical assessment of the Ki67 (MIB-1) and the proliferating cell nuclear antigen (PCNA). p53- and bcl-2 expression was analyzed immunohistochemically. A clinical-to-pathologic downstaging after radiochemotherapy was achieved in 25 of 32 patients (78%). During follow-up, tumor recurrence was observed in six cases. In one case, no residual tumor was detected after radiochemotherapy.
After radiochemotherapy, the apoptotic index increased significantly in almost every case examined. In contrast, the proliferative activity was significantly decreased in resected specimens as compared to biopsies. Bax immunostaining was detected in 12/31 (39%) biopsies and in 26/31 (84%) resected specimens. In the resected specimen, significantly more apoptotic cells that were bax-positive were found than in biopsies. Bcl-2 immunostaining occurred in 15/31 biopsies and 12/31 resected specimens, respectively. Tumors that were immunohistochemically negative for p53 (20/31 [65%]) generally exhibited a higher apoptotic index and a high expression level of bax than p53-positive tumors (11/31 [35%]). However, we did not find any correlation between the (pre- and post-therapeutic) rate of apoptosis or the level of bax expression and the degree of clinical-to-pathologic downstaging or the frequency of tumor recurrence.
Our results indicate that radiochemotherapy is associated with an increase in bax expression and also in apoptotic cell death. The observation of higher rates of apoptosis and bax in p53-negative tumors suggests that p53 might be a possible regulating factor of apoptosis in rectal cancer.
研究直肠癌在放化疗前后凋亡细胞死亡、增殖活性及凋亡调节蛋白表达之间的关系。
32例拟接受局部晚期直肠癌术前放化疗的患者,可获得治疗前活检标本及放化疗后的最终切除标本用于分析。采用原位末端标记(ISEL)技术鉴定并定量凋亡细胞。免疫组织化学法评估bax蛋白的表达。此外,对凋亡细胞和bax表达进行双重免疫染色。通过免疫组织化学评估Ki67(MIB-1)和增殖细胞核抗原(PCNA)来确定增殖活性。免疫组织化学法分析p53和bcl-2的表达。32例患者中有25例(78%)放化疗后实现了临床病理降期。随访期间,6例出现肿瘤复发。1例放化疗后未检测到残留肿瘤。
放化疗后,几乎在每个检测病例中凋亡指数均显著增加。相比之下,与活检标本相比,切除标本中的增殖活性显著降低。在31份活检标本中有12份(39%)检测到bax免疫染色,在31份切除标本中有26份(84%)检测到。在切除标本中,发现bax阳性的凋亡细胞明显多于活检标本。bcl-2免疫染色分别出现在31份活检标本中的15份和31份切除标本中的12份。p53免疫组织化学阴性的肿瘤(20/31 [65%])通常比p53阳性肿瘤(11/31 [35%])表现出更高的凋亡指数和更高的bax表达水平。然而,我们未发现(治疗前后)凋亡率或bax表达水平与临床病理降期程度或肿瘤复发频率之间存在任何相关性。
我们的结果表明,放化疗与bax表达增加以及凋亡细胞死亡增加有关。p53阴性肿瘤中凋亡率和bax较高的观察结果表明,p53可能是直肠癌凋亡的一个潜在调节因子。